GILEAD SCIENCES, INC. Tax Benefit from Stock Options Exercised (Deprecated 2013-01-31)
GILEAD SCIENCES, INC. (GILD) reported Tax Benefit from Stock Options Exercised (Deprecated 2013-01-31) of $38.91 million for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-08.
Discontinued › Expense Statement › Income Tax
us-gaap:TaxBenefitFromStockOptionsExercised1 · last filed 2013-05-08
- GILEAD SCIENCES, INC. tax benefit from stock options exercised (deprecated 2013-01-31) for the quarter ending 2013-03-31 was $38.91M, a 114.32% increase year-over-year.
- GILEAD SCIENCES, INC. tax benefit from stock options exercised (deprecated 2013-01-31) for the quarter ending 2012-12-31 was $51.23M, a 380.70% increase year-over-year.
- GILEAD SCIENCES, INC. tax benefit from stock options exercised (deprecated 2013-01-31) for the quarter ending 2012-09-30 was $30.60M, a 248.56% increase year-over-year.
- GILEAD SCIENCES, INC. tax benefit from stock options exercised (deprecated 2013-01-31) for the quarter ending 2012-06-30 was $12.65M.
- GILEAD SCIENCES, INC. tax benefit from stock options exercised (deprecated 2013-01-31) for fiscal 2012 was $112.63M, a 202.51% increase from fiscal 2011.
- GILEAD SCIENCES, INC. tax benefit from stock options exercised (deprecated 2013-01-31) for fiscal 2011 was $37.23M, a 54.64% decline from fiscal 2010.
- GILEAD SCIENCES, INC. tax benefit from stock options exercised (deprecated 2013-01-31) for fiscal 2010 was $82.09M.
| Period end | Tax Benefit from Stock Options Exercised (Deprecated 2013-01-31) 3 month | Tax Benefit from Stock Options Exercised (Deprecated 2013-01-31) 6 month | Tax Benefit from Stock Options Exercised (Deprecated 2013-01-31) 9 month | Tax Benefit from Stock Options Exercised (Deprecated 2013-01-31) 12 month |
|---|---|---|---|---|
| 2013-03-31 | $38.91M 10-Q · filed 2013-05-08 | $90.13M derived: sum of 2 quarters · filed 2013-05-08 | $120.73M derived: sum of 3 quarters · filed 2013-05-08 | $133.38M derived: sum of 4 quarters · filed 2013-05-08 |
| 2012-12-31 | $51.23M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $81.83M derived: sum of 2 quarters · filed 2013-02-27 | $94.48M derived: sum of 3 quarters · filed 2013-02-27 | $112.63M 10-K · filed 2013-02-27 |
| 2012-09-30 | $30.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $43.25M derived: sum of 2 quarters · filed 2012-11-06 | $61.40M 10-Q · filed 2012-11-06 | $72.06M derived: sum of 4 quarters · filed 2013-05-08 |
| 2012-06-30 | $12.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | $30.80M 10-Q · filed 2012-08-01 | $41.46M derived: sum of 3 quarters · filed 2013-05-08 | $50.24M derived: sum of 4 quarters · filed 2013-05-08 |
| 2012-03-31 | $18.15M 10-Q · filed 2013-05-08 | $28.81M derived: sum of 2 quarters · filed 2013-05-08 | $37.59M derived: sum of 3 quarters · filed 2013-05-08 | |
| 2011-12-31 | $10.66M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $19.43M derived: sum of 2 quarters · filed 2013-02-27 | $37.23M 10-K · filed 2013-02-27 | |
| 2011-09-30 | $8.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $26.57M 10-Q · filed 2012-11-06 | ||
| 2011-06-30 | $17.80M 10-Q · filed 2012-08-01 | |||
| 2010-12-31 | $82.09M 10-K · filed 2013-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |